ILMN — Illumina, Inc.

Summary of Illumina (ILMN) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $1.16 billion, up 9.5% year-over-year; organic growth of 6.5% (excluding China).
• EPS: Non-GAAP EPS of $1.31, a 10% increase year-over-year.
• Gross Margin: Non-GAAP gross margin at 68.2%, slightly better than expectations.
• Operating Margin: Non-GAAP operating margin of 22.5%, above guidance.
• Cash Flow: Cash flow from operations was $201 million; free cash flow was $162 million.
• Share Repurchases: 0.9 million shares repurchased for approximately $122 million.

2. Strategic Updates and Business Highlights

• Clinical Market Growth: Clinical markets, representing 65% of sequencing consumables revenue, grew 15% (excluding China), with strong performance in the U.S. and Canada.
• NovaSeq X Demand: Over 95 NovaSeq X instruments placed in Q2, with strong ongoing demand.
• Innovation: Launched new workflows, including whole genome MRD research and StrataMap Spatial, enhancing multi-omics capabilities.
• BioInsight Program: Progress in the Billion Cell Atlas initiative, with 300 million cells delivered and new partnerships formed, indicating strong biopharma interest.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year organic growth expected to exceed 5%, raised from 2%-4%. Total revenue guidance increased to $4.60 billion-$4.64 billion.
• EPS Guidance: Updated diluted EPS guidance to $5.30-$5.40, reflecting a year-over-year growth of 11%.
• Q3 Expectations: Anticipated organic revenue growth of approximately 4.5%, with reported revenue of $1.14 billion-$1.16 billion.

4. Challenges and Points of Concern

• Research Market: Research and applied markets saw a decline of 7% in consumables, with ongoing funding uncertainty impacting growth.
• Transition Dynamics: The transition to NovaSeq X may lead to temporary revenue fluctuations as older models are phased out.
• Cost Pressures: Continued inflationary pressures, particularly in memory and freight costs, could impact margins despite management's efforts to mitigate these effects.

5. Notable Q&A Insights

• Clinical Growth Momentum: Management expressed confidence in sustained clinical growth, dismissing concerns about a potential "clinical cliff" and emphasizing ongoing demand.
• Instrument Placement Dynamics: There was a discussion on the potential headwinds from transitioning customers from older models, but management remained optimistic about the long-term benefits of increased NovaSeq X placements.
• Market Environment: Some analysts raised concerns about the slower growth in clinical consumables and the impact of macroeconomic conditions on mid-throughput instruments, which management acknowledged but remained confident in their overall strategy and market position.
• AI and Multi-Omics: Excitement around AI-related initiatives and multi-omics capabilities was highlighted, with expectations for these areas to contribute to future growth.

Overall, Illumina reported a strong Q2 2026 performance, raising guidance and showcasing robust demand in clinical markets, while also navigating challenges in research and cost pressures.